COMPANY
Ironwood Pharmaceuticals
Timeline
- Trial start 2: A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome source ↗
- Trial start Phase 1: A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects source ↗
- Trial start Phase 1: A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers source ↗
- Trial start Phase 2: A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome source ↗
- Trial start Phase 1: Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers source ↗
- Trial start Phase 3: Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) source ↗
- Trial start Phase 3: A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) source ↗
- Trial start Phase 3: A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) source ↗
- Trial start 4: A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment source ↗
- Trial start Phase 4: A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) source ↗
- Trial start Phase 2: A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) source ↗
- Trial start Phase 2: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) source ↗
- Trial start Phase 3: Trial of Linaclotide in Patients With Chronic Idiopathic Constipation source ↗
- Trial start Phase 2: Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) source ↗
- Trial start Phase 2: Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors source ↗
- Trial start 2: Phase 2a Study of IW-9179 to Treat Functional Dyspepsia source ↗
- Trial start Phase 2: Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction source ↗
- Trial start Phase 3: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) source ↗
- Trial start Phase 3: An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation source ↗
- Trial start Phase 3: Trial of Linaclotide in Patients With Chronic Constipation source ↗
- Trial start 2: Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) source ↗
- Trial start 2: Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation source ↗
- Trial start Phase 2: Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia source ↗
- Trial start 2: Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation source ↗
- Trial start 2: Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS source ↗
Clinical trials (lead sponsor) 25
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05740007 | A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | 2 | Terminated | Mar 28, 2023 | Jan 23, 2025 (actual) |
| NCT05362695 | A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects | Phase 1 | Completed | May 17, 2022 | Jun 30, 2022 (actual) |
| NCT05188261 | A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers | Phase 1 | Completed | Jan 18, 2022 | Mar 9, 2022 (actual) |
| NCT01107236 | Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction | Phase 2 | Completed | 2010-06 | 2010-08 (actual) |
| NCT02837783 | A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 4 | Terminated | Dec 21, 2016 | Oct 31, 2018 (actual) |
| NCT03226899 | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment | 4 | Terminated | Jul 19, 2017 | Feb 25, 2019 (actual) |
| NCT03561090 | A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) | Phase 3 | Terminated | Jun 20, 2018 | Oct 7, 2020 (actual) |
| NCT03561883 | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) | Phase 3 | Completed | Sep 6, 2018 | Jul 28, 2020 (actual) |
| NCT03931785 | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome | Phase 2 | Completed | May 1, 2019 | Feb 26, 2020 (actual) |
| NCT03573908 | A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Completed | Jun 20, 2018 | Mar 13, 2019 (actual) |
| NCT02559206 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 2 | Completed | Oct 22, 2015 | Sep 30, 2016 (actual) |
| NCT02637557 | A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) | Phase 2 | Completed | Mar 1, 2016 | Apr 26, 2017 (actual) |
| NCT03856970 | Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers | Phase 1 | Completed | Mar 11, 2019 | Jun 25, 2019 (actual) |
| NCT00730171 | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Phase 3 | Completed | 2008-09 | 2012-03 (actual) |
| NCT02291679 | Trial of Linaclotide in Patients With Chronic Idiopathic Constipation | Phase 3 | Completed | 2014-10 | 2015-08 (actual) |
| NCT02289846 | Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) | Phase 2 | Completed | 2014-10 | 2015-12 (actual) |
| NCT02030925 | Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors | Phase 2 | Completed | 2014-02 | 2014-12 (actual) |
| NCT01712412 | Phase 2a Study of IW-9179 to Treat Functional Dyspepsia | 2 | Terminated | 2012-10 | 2014-02 (actual) |
| NCT00938717 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Completed | 2009-07 | 2010-09 (actual) |
| NCT00402337 | Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation | 2 | Completed | 2006-11 | 2007-12 (actual) |
| NCT00460811 | Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | 2 | Completed | 2007-04 | 2008-02 (actual) |
| NCT00730015 | Trial of Linaclotide in Patients With Chronic Constipation | Phase 3 | Completed | 2008-08 | 2009-08 (actual) |
| NCT00306748 | Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation | 2 | Completed | 2006-03 | Not listed |
| NCT00404001 | Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia | Phase 2 | Completed | 2006-11 | Not listed |
| NCT00258193 | Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS | 2 | Completed | 2006-01 | Not listed |